Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trialRaches Ella, Siddhartha Dutta, Sagar Vivek Redkar et al.|The Lancet|2021Cited by 361
First isolation of SARS-CoV-2 from clinical samples in IndiaPrasad Sarkale, Priya Abraham, Savita Patil et al.|The Indian Journal of Medical Research|2020Cited by 120
Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trialRaches Ella, Siddarth Reddy, William C. Blackwelder et al.|medRxiv|2021Cited by 80
SARS CoV-2 variant B.1.617.1 is highly pathogenic in hamsters than B.1 variantPragya D. Yadav, Balram Bhargava, Sreelekshmy Mohandas et al.|bioRxiv (Cold Spring Harbor Laboratory)|2021Cited by 60
Genomic analysis of SARS-CoV-2 strains among Indians returning from Italy, Iran & China, & Italian tourists in IndiaVarsha Potdar, Priya Abraham, Manohar Lal Choudhary et al.|The Indian Journal of Medical Research|2020Cited by 52